B. Metzler seel. Sohn & Co. AG Cuts Holdings in Amgen Inc. $AMGN

Key Points

• B. Metzler seel. Sohn & Co. AG cut its Amgen holdings by 10.4% in the second quarter, selling 4,539 shares and retaining 39,041 shares valued at approximately $14.1 million.
• Amgen reported quarterly EPS of $6.29 and revenue of $10.05 billion, exceeding analyst estimates, while revenue rose 9.5% year over year. The stock opened at $433.73, near its 52-week high of $443.20.
• Analyst sentiment remains mixed: several firms raised price targets or upgraded the stock, but the consensus rating is still “Hold” with a target price of $380.43. Amgen also declared a quarterly dividend of $2.52 per share, representing a 2.3% yield.

B. Metzler seel. Sohn & Co. AG lowered its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,041 shares of the medical research company's stock after selling 4,539 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Amgen were worth $14,137,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of AMGN. Impax Asset Management Group plc lifted its holdings in shares of Amgen by 4.6% during the second quarter. Impax Asset Management Group plc now owns 18,289 shares of the medical research company's stock valued at $6,623,000 after purchasing an additional 796 shares in the last quarter. Portfolio Design Labs LLC increased its holdings in Amgen by 7.8% in the 2nd quarter. Portfolio Design Labs LLC now owns 3,317 shares of the medical research company's stock worth $1,201,000 after buying an additional 239 shares in the last quarter. Advisors Capital Management LLC raised its position in Amgen by 0.8% in the 2nd quarter. Advisors Capital Management LLC now owns 73,921 shares of the medical research company's stock worth $26,768,000 after buying an additional 601 shares during the last quarter. E Fund Management Co. Ltd. raised its position in Amgen by 6.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 23,015 shares of the medical research company's stock worth $8,334,000 after buying an additional 1,487 shares during the last quarter. Finally, MSH Capital Advisors LLC lifted its stake in Amgen by 6.5% during the 2nd quarter. MSH Capital Advisors LLC now owns 1,022 shares of the medical research company's stock valued at $370,000 after acquiring an additional 62 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Unusually heavy call-option activity points to increased bullish positioning. Investors purchased 79,035 call options, roughly 931% above typical volume, although options activity is speculative and does not guarantee future gains.
• Positive Sentiment: Argus raised its price target from $375 to $460 and upgraded Amgen to “Buy,” adding to the series of favorable analyst views. Argus price target report
• Positive Sentiment: Mizuho and Cantor Fitzgerald analysts also projected further appreciation for Amgen, reinforcing the bullish sentiment around the company’s earnings performance and pipeline. Mizuho Amgen forecast Cantor Fitzgerald Amgen outlook
• Positive Sentiment: Amgen has outperformed several major drugmakers in 2026, attracting investor interest as markets favor profitable pharmaceutical companies even without an obesity-drug franchise. Drugmaker stock performance comparison
• Neutral Sentiment: Biotech ETFs are benefiting from innovation, obesity-drug demand and merger activity, creating a favorable sector backdrop, though the article does not identify a specific new catalyst for Amgen. Biotech ETF growth article
• Negative Sentiment: Industry caution around obesity-drug development is a risk: investors are penalizing undifferentiated programs, and Amgen has reportedly trimmed some early-stage efforts. Obesity drug investment outlook

Analyst Ratings Changes

A number of brokerages have recently issued reports on AMGN. Daiwa Securities Group dropped their price target on shares of Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a report on Wednesday, May 13th. Barclays boosted their price objective on shares of Amgen from $360.00 to $380.00 and gave the company an "equal weight" rating in a report on Friday, August 14th. Bank of America increased their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Oppenheimer boosted their target price on shares of Amgen from $400.00 to $450.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $380.43.

Amgen Price Performance

NASDAQ AMGN opened at $433.73 on Friday. The company has a 50-day moving average price of $377.35 and a 200-day moving average price of $361.40. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $443.20. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market capitalization of $234.49 billion, a P/E ratio of 26.96, a PEG ratio of 4.09 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm's revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.89 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen's payout ratio is presently 62.65%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source